CytomX Therapeutics (CTMX) Financials

$3.75

$0.08 (2.04%)

As on 02-Sep-2026 15:34EDT

Market cap

$699 Mln

Revenue (TTM)

$18 Mln

P/E Ratio

--

P/B Ratio

2.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	18.30	76.20	138.10	101.21	53.16	69.57
Cost of Revenue	0.76	--	1.77	2.18	5.86	5.84
Gross Profit	18.05	76.20	138.10	101.21	53.16	69.57
Operating Expenses	105.20	98.57	113.11	107.70	154.50	153.35
Operating Profit (EBIT)	-87.15	-22.36	25.00	-6.48	-101.34	-83.78
Other Income	--	--	--	--	0.17	0.17
Profit before Tax	-79.42	-17.13	32.09	3.32	-99.32	-83.61
Provision for Tax	0.23	0.24	0.22	3.89	-2.02	-2.96
Profit after Tax (Net Income)	-79.65	-17.37	31.87	-0.57	-97.30	-80.65
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-115.87	-83.61

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	302.07	99.01	-0.46	-47.45	-85.75	89.38
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	39.30	5.94	35.22	93.33	194.03	143.72
Current Liabilities	39.86	46.62	85.77	155.91	152.61	106.32
Total Liabilities	421.09	151.57	120.53	201.79	260.89	339.41

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	8.07	7.65	13.23	18.86	23.79	29.11
Current Assets	373.16	143.92	107.31	182.94	237.10	310.30
Total Assets	421.09	151.57	120.53	201.79	260.89	339.41
Total Debt*	5.70	4.24	9.39	13.97	18.06	18.06
Net Current Assets	333.29	97.31	21.53	27.02	84.49	203.99

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-75.59	-86.23	-56.04	-110.79	-119.03
Cash Flow from Investing Activities	--	-59.74	99.70	-150.67	98.26	22.49
Cash from Financing Activities	--	110.45	7.52	30.23	0.65	110.21
Net Cash Inflow / Outflow	--	--	--	--	13.67	13.67

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.44	-0.10	0.40	-0.01	-1.47	-1.24
Cash EPS ($)	--	-0.09	0.42	0.03	-1.43	-1.20
Adjusted Book Value ($)	--	0.58	--	--	--	1.37
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.44	-1.08	-0.83	-1.67	-1.83
Free Cash Flow per Share ($)	--	-0.45	-1.08	-0.84	-1.70	-1.85

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-30.97	-259.69	1.12	-489.67	-129.52
ROE (%)	-39.72	-35.25	-133.06	0.85	-5,363.78	-197.65
ROA (%)	-25.07	-12.77	19.77	-0.25	-32.42	-23.11
EBIT Margin (%)	-433.95	-22.48	23.24	3.28	-190.61	-120.42
Net Margin (%)	-435.21	-22.79	23.08	-0.56	-182.43	-115.63
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-87.03	-0.45	0.36	0.90	-0.24	0.02
EBIT Growth (%)	-264.67	-153.38	865.78	103.28	-20.95	-4.02
Net Profit Growth (%)	-266.00	-154.50	5,700.88	99.42	-20.65	-24.42
EPS Growth (%)	-176.84	-1.26	48.07	0.99	-0.19	0.12
Book Value Growth (%)	48.51	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-41.74	2.59	-183.36	-1.09	-3.50
Price / Book Value	2.47	7.32	-180.93	-2.20	-1.24	3.16
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	24.67	-37.59	-0.26	-10.22	1.71	0.06
Close Price ($)	3.75	4.26	1.03	1.55	1.60	4.33
High Price ($)	8.21	4.62	5.85	3.02	4.73	10.05
Low Price ($)	1.72	0.40	0.83	1.04	1.17	3.68
Market Cap ($ Cr)	699.46	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.04	-20.58	-0.29	-0.21	0.20
Short term debt to equity ratio	0.00	0.04	-11.28	-0.10	-0.05	0.04
Current Ratio	9.36	3.09	1.25	1.17	1.55	2.92
Quick Ratio	9.36	--	--	--	1.55	2.92
Interest Coverage	--	--	--	--	-50.22	-487.10

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	204.86	2.64	2.25	3.39	67.69	1.14
Asset Turnover	0.06	0.56	0.86	0.44	0.18	0.20
Receivable days	--	12.26	8.64	71.12	126.33	4.17
Inventory Days	--	--	--	0.00	0.00	0.00
Payable days	--	--	262.99	358.28	175.48	181.84
Cash Conversion Cycle	--	--	--	-287.16	-49.15	-177.67

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.